Please Wait.....
Report
Global Therapeutic Vaccines Market By Product (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, Others) , By Technology (Allogeneic Vaccine, Autologous Vaccine) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Market Report I 2024-08-01 I 300 Pages I Allied Market Research
Therapeutic Vaccines Market Expected to Garner $135.7 Billion by 2033, Growing at a CAGR of 19.1%
Abstract:The global therapeutic vaccines market is expected to grow primarily due to the growing prevalence of chronic diseases & infectious ailments and technological advancements in vaccine development. The Asia-Pacific region is predicted to witness profitable growth by 2033.
As per the report published by Research Dive, the global therapeutic vaccines market was valued at $26.7billion in 2023 and is expected to register a revenue of $135.7billion by 2033 at a CAGR of 19.1% during the forecast period 2024-2033.
Dynamics of the Market
The increasing incidence of diseases such as cancer, HIV, and neurological and autoimmune diseases, and the growing demand for personalized medicine & targeted therapies are expected to make the therapeutic vaccines market a highly profitable one in the forecast period. Besides, the increased funding and initiatives from governments & NGOs and the expanding applications of therapeutic vaccines beyond infectious diseases are other factors predicted to boost the market growth.
However, according to market analysts, high production costs, complex manufacturing processes, and stringent approval requirements might restrain the growth of the market.
Technological advancements, integration of machine learning & artificial intelligence in vaccine design & development, and growing investments in R&D are predicted to offer numerous growth opportunities for the therapeutics vaccines market in the forecast period. Moreover, continued investments by major market players accelerate vaccine development and availability.
Key Players of the Market
The major players of the therapeutic vaccines market include Agenus Inc., Celldex Therapeutic Inc., Argos Therapeutic Inc., Dendreon Pharmaceuticals LLC, Merck & Co. Inc., GSK plc, Novartis AG, Phio Pharmaceuticals Corp., Pfizer, Inc., AstraZeneca, INOVIO Pharmaceuticals, and BioNTech SE.
What the Report Covers
In addition to the details highlighted in this description, the comprehensive final report delves into essential market aspects. These encompass a market overview, SWOT analysis, market dynamics, Porter's five forces analysis, segmentation (key trends, regional analysis, and forecast analysis), and company profiles (including company overview, product portfolio, operating segments, strategic initiatives, and financial performance).
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Product Benchmarking / Product specification and applications
- Upcoming/New Entrant by Regions
- Technology Trend Analysis
- Market share analysis of players by products/segments
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Criss-cross segment analysis- market size and forecast
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- Market share analysis of players at global/region/country level
- SWOT Analysis
Key Market Segments
By Product
- Autoimmune Disease Vaccines
- Neurological Disease Vaccines
- Cancer Vaccines
- Infectious Disease Vaccines
- Others
By Technology
- Allogeneic Vaccine
- Autologous Vaccine
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- UAE
- Rest of LAMEA
- Key Market Players
- Agenus Inc.
- Argos Therapeutics, Inc.
- Celldex Therapeutics Inc.
- Dendreon Pharmaceuticals LLC
- GSK plc.
- Merck & Co. Inc.
- Novartis AG
- Pfizer, Inc.
- AstraZeneca
- BioNTech SE
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: THERAPEUTIC VACCINES MARKET, BY PRODUCT
4.1. Market Overview
4.1.1 Market Size and Forecast, By Product
4.2. Autoimmune Disease Vaccines
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Neurological Disease Vaccines
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Cancer Vaccines
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Infectious Disease Vaccines
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
4.6. Others
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, By Region
4.6.3. Market Share Analysis, By Country
CHAPTER 5: THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY
5.1. Market Overview
5.1.1 Market Size and Forecast, By Technology
5.2. Allogeneic Vaccine
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Autologous Vaccine
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: THERAPEUTIC VACCINES MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Product
6.2.3. Market Size and Forecast, By Technology
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Therapeutic Vaccines Market
6.2.5.1. Market Size and Forecast, By Product
6.2.5.2. Market Size and Forecast, By Technology
6.2.6. Canada Therapeutic Vaccines Market
6.2.6.1. Market Size and Forecast, By Product
6.2.6.2. Market Size and Forecast, By Technology
6.2.7. Mexico Therapeutic Vaccines Market
6.2.7.1. Market Size and Forecast, By Product
6.2.7.2. Market Size and Forecast, By Technology
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Product
6.3.3. Market Size and Forecast, By Technology
6.3.4. Market Size and Forecast, By Country
6.3.5. France Therapeutic Vaccines Market
6.3.5.1. Market Size and Forecast, By Product
6.3.5.2. Market Size and Forecast, By Technology
6.3.6. Germany Therapeutic Vaccines Market
6.3.6.1. Market Size and Forecast, By Product
6.3.6.2. Market Size and Forecast, By Technology
6.3.7. Italy Therapeutic Vaccines Market
6.3.7.1. Market Size and Forecast, By Product
6.3.7.2. Market Size and Forecast, By Technology
6.3.8. Spain Therapeutic Vaccines Market
6.3.8.1. Market Size and Forecast, By Product
6.3.8.2. Market Size and Forecast, By Technology
6.3.9. UK Therapeutic Vaccines Market
6.3.9.1. Market Size and Forecast, By Product
6.3.9.2. Market Size and Forecast, By Technology
6.3.10. Rest Of Europe Therapeutic Vaccines Market
6.3.10.1. Market Size and Forecast, By Product
6.3.10.2. Market Size and Forecast, By Technology
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Product
6.4.3. Market Size and Forecast, By Technology
6.4.4. Market Size and Forecast, By Country
6.4.5. China Therapeutic Vaccines Market
6.4.5.1. Market Size and Forecast, By Product
6.4.5.2. Market Size and Forecast, By Technology
6.4.6. Japan Therapeutic Vaccines Market
6.4.6.1. Market Size and Forecast, By Product
6.4.6.2. Market Size and Forecast, By Technology
6.4.7. India Therapeutic Vaccines Market
6.4.7.1. Market Size and Forecast, By Product
6.4.7.2. Market Size and Forecast, By Technology
6.4.8. South Korea Therapeutic Vaccines Market
6.4.8.1. Market Size and Forecast, By Product
6.4.8.2. Market Size and Forecast, By Technology
6.4.9. Australia Therapeutic Vaccines Market
6.4.9.1. Market Size and Forecast, By Product
6.4.9.2. Market Size and Forecast, By Technology
6.4.10. Rest of Asia-Pacific Therapeutic Vaccines Market
6.4.10.1. Market Size and Forecast, By Product
6.4.10.2. Market Size and Forecast, By Technology
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Product
6.5.3. Market Size and Forecast, By Technology
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Therapeutic Vaccines Market
6.5.5.1. Market Size and Forecast, By Product
6.5.5.2. Market Size and Forecast, By Technology
6.5.6. South Africa Therapeutic Vaccines Market
6.5.6.1. Market Size and Forecast, By Product
6.5.6.2. Market Size and Forecast, By Technology
6.5.7. Saudi Arabia Therapeutic Vaccines Market
6.5.7.1. Market Size and Forecast, By Product
6.5.7.2. Market Size and Forecast, By Technology
6.5.8. UAE Therapeutic Vaccines Market
6.5.8.1. Market Size and Forecast, By Product
6.5.8.2. Market Size and Forecast, By Technology
6.5.9. Rest of LAMEA Therapeutic Vaccines Market
6.5.9.1. Market Size and Forecast, By Product
6.5.9.2. Market Size and Forecast, By Technology
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping Of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Agenus Inc.
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Argos Therapeutics, Inc.
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Celldex Therapeutics Inc.
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Dendreon Pharmaceuticals LLC
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. GSK Plc.
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Merck And Co. Inc.
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Novartis AG
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Pfizer, Inc.
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. AstraZeneca
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. BioNTech SE
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. GLOBAL THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 2. THERAPEUTIC VACCINES MARKET FOR AUTOIMMUNE DISEASE VACCINES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 3. THERAPEUTIC VACCINES MARKET FOR NEUROLOGICAL DISEASE VACCINES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 4. THERAPEUTIC VACCINES MARKET FOR CANCER VACCINES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 5. THERAPEUTIC VACCINES MARKET FOR INFECTIOUS DISEASE VACCINES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 6. THERAPEUTIC VACCINES MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 7. GLOBAL THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 8. THERAPEUTIC VACCINES MARKET FOR ALLOGENEIC VACCINE, BY REGION, 2024 - 2033 ($MILLION)
TABLE 9. THERAPEUTIC VACCINES MARKET FOR AUTOLOGOUS VACCINE, BY REGION, 2024 - 2033 ($MILLION)
TABLE 10. THERAPEUTIC VACCINES MARKET, BY REGION, 2024 - 2033 ($MILLION)
TABLE 11. NORTH AMERICA THERAPEUTIC VACCINES MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 12. NORTH AMERICA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 13. NORTH AMERICA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 14. U.S. THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 15. U.S. THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 16. CANADA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 17. CANADA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 18. MEXICO THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 19. MEXICO THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 20. EUROPE THERAPEUTIC VACCINES MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 21. EUROPE THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 22. EUROPE THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 23. FRANCE THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 24. FRANCE THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 25. GERMANY THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 26. GERMANY THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 27. ITALY THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 28. ITALY THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 29. SPAIN THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 30. SPAIN THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 31. UK THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 32. UK THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 33. REST OF EUROPE THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 34. REST OF EUROPE THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 35. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 36. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 37. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 38. CHINA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 39. CHINA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 40. JAPAN THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 41. JAPAN THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 42. INDIA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 43. INDIA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 44. SOUTH KOREA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 45. SOUTH KOREA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 46. AUSTRALIA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 47. AUSTRALIA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 50. LAMEA THERAPEUTIC VACCINES MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 51. LAMEA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 52. LAMEA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 53. BRAZIL THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 54. BRAZIL THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 55. SOUTH AFRICA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 56. SOUTH AFRICA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 57. SAUDI ARABIA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 58. SAUDI ARABIA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 59. UAE THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 60. UAE THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 61. REST OF LAMEA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 62. REST OF LAMEA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 63. AGENUS INC.: KEY EXECUTIVES
TABLE 64. AGENUS INC.: COMPANY SNAPSHOT
TABLE 65. AGENUS INC.: OPERATING SEGMENTS
TABLE 66. AGENUS INC.: PRODUCT PORTFOLIO
TABLE 67. AGENUS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 68. ARGOS THERAPEUTICS, INC.: KEY EXECUTIVES
TABLE 69. ARGOS THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 70. ARGOS THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 71. ARGOS THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 72. ARGOS THERAPEUTICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 73. CELLDEX THERAPEUTICS INC.: KEY EXECUTIVES
TABLE 74. CELLDEX THERAPEUTICS INC.: COMPANY SNAPSHOT
TABLE 75. CELLDEX THERAPEUTICS INC.: OPERATING SEGMENTS
TABLE 76. CELLDEX THERAPEUTICS INC.: PRODUCT PORTFOLIO
TABLE 77. CELLDEX THERAPEUTICS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 78. DENDREON PHARMACEUTICALS LLC: KEY EXECUTIVES
TABLE 79. DENDREON PHARMACEUTICALS LLC: COMPANY SNAPSHOT
TABLE 80. DENDREON PHARMACEUTICALS LLC: OPERATING SEGMENTS
TABLE 81. DENDREON PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 82. DENDREON PHARMACEUTICALS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 83. GSK PLC.: KEY EXECUTIVES
TABLE 84. GSK PLC.: COMPANY SNAPSHOT
TABLE 85. GSK PLC.: OPERATING SEGMENTS
TABLE 86. GSK PLC.: PRODUCT PORTFOLIO
TABLE 87. GSK PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 88. MERCK AND CO. INC.: KEY EXECUTIVES
TABLE 89. MERCK AND CO. INC.: COMPANY SNAPSHOT
TABLE 90. MERCK AND CO. INC.: OPERATING SEGMENTS
TABLE 91. MERCK AND CO. INC.: PRODUCT PORTFOLIO
TABLE 92. MERCK AND CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 93. NOVARTIS AG: KEY EXECUTIVES
TABLE 94. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 95. NOVARTIS AG: OPERATING SEGMENTS
TABLE 96. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 97. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 98. PFIZER, INC.: KEY EXECUTIVES
TABLE 99. PFIZER, INC.: COMPANY SNAPSHOT
TABLE 100. PFIZER, INC.: OPERATING SEGMENTS
TABLE 101. PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 102. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 103. ASTRAZENECA: KEY EXECUTIVES
TABLE 104. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 105. ASTRAZENECA: OPERATING SEGMENTS
TABLE 106. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 107. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 108. BIONTECH SE: KEY EXECUTIVES
TABLE 109. BIONTECH SE: COMPANY SNAPSHOT
TABLE 110. BIONTECH SE: OPERATING SEGMENTS
TABLE 111. BIONTECH SE: PRODUCT PORTFOLIO
TABLE 112. BIONTECH SE: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL THERAPEUTIC VACCINES MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF THERAPEUTIC VACCINES MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN THERAPEUTIC VACCINES MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALTHERAPEUTIC VACCINES MARKET
FIGURE 10. GLOBAL THERAPEUTIC VACCINES MARKET SEGMENTATION, BY PRODUCT
FIGURE 11. THERAPEUTIC VACCINES MARKET FOR AUTOIMMUNE DISEASE VACCINES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 12. THERAPEUTIC VACCINES MARKET FOR NEUROLOGICAL DISEASE VACCINES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 13. THERAPEUTIC VACCINES MARKET FOR CANCER VACCINES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 14. THERAPEUTIC VACCINES MARKET FOR INFECTIOUS DISEASE VACCINES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 15. THERAPEUTIC VACCINES MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 16. GLOBAL THERAPEUTIC VACCINES MARKET SEGMENTATION, BY TECHNOLOGY
FIGURE 17. THERAPEUTIC VACCINES MARKET FOR ALLOGENEIC VACCINE, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 18. THERAPEUTIC VACCINES MARKET FOR AUTOLOGOUS VACCINE, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 23. COMPETITIVE DASHBOARD
FIGURE 24. COMPETITIVE HEATMAP: THERAPEUTIC VACCINES MARKET
FIGURE 25. TOP PLAYER POSITIONING, 2023
FIGURE 26. AGENUS INC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 27. AGENUS INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 28. AGENUS INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 29. ARGOS THERAPEUTICS, INC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 30. ARGOS THERAPEUTICS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 31. ARGOS THERAPEUTICS, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 32. CELLDEX THERAPEUTICS INC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 33. CELLDEX THERAPEUTICS INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 34. CELLDEX THERAPEUTICS INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 35. DENDREON PHARMACEUTICALS LLC: NET SALES, 2021-2023 ($MILLION)
FIGURE 36. DENDREON PHARMACEUTICALS LLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 37. DENDREON PHARMACEUTICALS LLC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 38. GSK PLC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 39. GSK PLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 40. GSK PLC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 41. MERCK AND CO. INC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 42. MERCK AND CO. INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. MERCK AND CO. INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 44. NOVARTIS AG: NET SALES, 2021-2023 ($MILLION)
FIGURE 45. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. NOVARTIS AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 47. PFIZER, INC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 48. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. PFIZER, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 50. ASTRAZENECA: NET SALES, 2021-2023 ($MILLION)
FIGURE 51. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 52. ASTRAZENECA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 53. BIONTECH SE: NET SALES, 2021-2023 ($MILLION)
FIGURE 54. BIONTECH SE: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 55. BIONTECH SE: REVENUE SHARE, BY REGION, 2023 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security